You are here

Our science / Clinical Trials / Find a Trial / NCT00584519

Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight

Back to Search Print Save as PDF Bookmark Trial

NCT00584519

Last updated on December 5, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder
(DSM-IV TR)

- Patients with BMI (body mass index) more or equal to 25 Kg/m2

- Patients or their legal representative have provided written informed consent

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients are unable to complete or to understand health questionnaires in Spanish
language

- Patients are currently enrolled on clinical trials or other investigational studies

NCT00584519
Pfizer
Completed
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Similar Trials

Schizophrenia
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
NCT00265551
All Genders
18+
Years
Multiple Sites
Schizophrenia
Treatment of Schizophrenic Patients With Ziprasidone
NCT00579670
All Genders
18+
Years
Multiple Sites
Schizophrenia
Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia
NCT00139737
All Genders
18+
Years
Multiple Sites
Schizophrenia
Study Comparing Bioavailability of Oral Formulations of Vabicaserin
NCT00541996
Males
18+
Years
Philadelphia, Pennsylvania
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight (CRESSOB)

To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months.

To analyse the perceived health status and the level of functioning and disability of patients with schizophrenia and overweight and their progress at 3, 6 and 12 months.

To assess the progress of the symptoms of the disease at 6 and 12 months.
Consecutive patient sampling. Any investigational site four consecutive patients with diagnosis of Schizophrenia (DSM-IV TR) and Overweight (BMI more or equal to 25 Kg/m2)
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Community sample. Patients >17 years older with diagnosis of Schizophrenia (DSM-IV TR) and Overweight (BMI more or equal to 25 Kg/m2)
Schizophrenia
Other: non-interventional
non-interventional
500 patients
Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) with BMI (body mass index) more or equal to 25 Kg/m2
Intervention: Other: non-interventional
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
430
June 2009
June 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR)
  • Patients with BMI (body mass index) more or equal to 25 Kg/m2
  • Patients or their legal representative have provided written informed consent

Exclusion Criteria:

  • Patients are unable to complete or to understand health questionnaires in Spanish language
  • Patients are currently enrolled on clinical trials or other investigational studies
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00584519
A1281162
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer Inc
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2010

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now